Taiwan News57m
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic response (CCyR) rate was approximately 61% and the major molecular response (MMR ... confirmed by a validated ...
BMJ15m
Adherence to cervical cancer screening in France: factors influencing the healthcare professionals’ decisions—a qualitative study
Objective To understand what leads to the non-adherence to the cervical cancer screening (CCS) recommendations during a consultation. Design For this qualitative study, in-depth semistructured ...